Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative.
Novo’s steady insulin cash flows and new MASH bet could expand growth beyond its core diabetes focus.
Discover how Novo Nordisk (NYSE: NVO) stacks up against Eli Lilly (NYSE: LLY) in the obesity and metabolic race, from GLP‑1 leadership to NASH/MASH optionality and dividend appeal. Watch the video below to see which profile fits your portfolio.
*This video was published on Jun. 26, 2026.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Before you buy stock in Novo Nordisk, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $382,359!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,201,390!*
Now, it’s worth noting Stock Advisor’s total average return is 883% — a market-crushing outperformance compared to 205% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of June 26, 2026.
Alicia Alfiere, MBA has no position in any of the stocks mentioned. Danny Vena, CPA has no position in any of the stocks mentioned. Karl Thiel has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a disclosure policy.